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  Young male rats of Wistar strain were divided into severa／ experimental groups， each con－
sisting of 30 animals， and ’fed on diffe．Tent diet as follows ： ．
  Group A ： vitamin B6 deficient basal diet with O．04 ％ 2－acetylaminofluorene （2－AAF）
  ．Group．B二same as group A plus 1．4．％d，1－tryptophan
  Group C： same as group B plus suthcient quantity of vitamin B6 （pyridoxal phosphate）．
  The lanimals of each group were sacrificed at 9， 15 and 30 weeks． Various organs including the ．
bladdet ar d liver Twere hlstologically exarriined． Calculation Qf labeling index of 3HrTdR（6－nT）
uptake by the urinary bladder mucosa as well as measurement of liver function by indocyanine
green test （1．C． G． test） was accomplisihed． Orally given 2－AAF gave typical damages to the
liver wi’thin－9weeks， causing cystic formation， hyperplastic nodule and proliferation of tubular
duct with負brosis． So皿e significant relationships．were observed among relatiVe weight of the．
liver， 1．C． G． test and labeling index Qf．the bladder mucosa．
  On the oth． er hand， the bladder．epithelium turned its nature as time goes on and the epithelial
hyperplasia was observed 15 weeks after・initiation， then sbme of them altered to papillary tumer
of the bladder． There must be more complicated factors between hyperplasia and cancer forma－
tion which is an irreversible process． There was apparently negative correlation between serum
retention rates of 1． C． G． and labeling indices of the bladder mucosa at 15 and 30 weeks in each
group．
  This sugg’ests presence of some activation mechan’isni in the rat which will rnetabolite carcino－
gens to rnore proximate substances by passing through liver cells． The mechanisrti’niay be
consistent with so－called “liverLbladderaxis” which Melieow and others advocated previouslY．
  Althottgh tryptophan－annexed diet’ih group B and C gave a protecting effect tb the liver













































実 験 方 法
実験食A．ビタミンB6欠乏基礎食餌に2－AAF
     O，04重：量パーセント添加
実験食B．上記のA．にd，1－tryptophan 1．4重
     量パーセント添加．
実験食C．上記のB．にvitamin B6（pyridoxal
     phosphate） 8 mg／k9添加．
Table 2．ビタミンB6欠乏基礎食餌組成表
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           叫Jndocyanine green exchange comPartment model
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 ただし，A， B， K1， K2は常数
 理論消失曲線 C＝4e－K・t＋Be－K2t
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実 験 結 果
 ユ．実験食投与ラットの体重変化
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             （H－E染色，×150）
Photo 3腺性化生を示す肝細胞癌がみられる．




      警潔遍   護．
     Photo．4．細胆管増生が著しい．





     再生肝細胞において3H－TdRのとりこみ
 が著明である．一方では細胆管増生の部分に嚢胞
 形成がみられる．     （H－E染色                 ×60）
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Photo． 5．肝細胞の変性像と嚢胞形成がみられる．
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Photo．9．膀胱粘膜細胞の増生がみられ，粘膜面の
                    × 150）不規則な凹凸がみられる， （H－E染色
Photo．10．膀胱粘膜にみられた乳頭腫
           （H－E染色 ×60）
Photo．11．移行上皮癌
        （H－E染色 ×60）
原田：実験的膀胱腫瘍
Table 5．肝摘出重量ならびに対体重比
      （対照比は各群の対照を1．00とする）
    Table 6．病理組織学的所見
i）膀胱における変化
581
臨差，調対樋比対照比 実験鯛（週）「 Hyperplasia 1 Bladder tumor
第1?栫m19．。土拶
   B l20．5±12．1i
   C    21．9土 4．2
  対照期14・6± O・5i
第30週経過時i     I          創：1：1劃
               対照群13．7±1．7［
     i
6．2 × lo－4 1 2．03
7．9×10－4 ll 2．62
s．s x lo－4 1 ！．gl
     l
3．0×！0－4 i  ！．00
      10．O×10－4
      9．2×10－4
34．5± 7．9 i 10．2×10－4




























































































Lyrnphosarcoma ； l sweeks C－1
Squamous cell carcinoma of external auditory
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Fig，4。各平均値間の比較による相関関係（rl 5， r30はそれぞれ15，30週目における相関係数を示す）
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Fig． 6． Liver relative body weight and ICG
 result．

















g’noup A rp．1 C ， ，A B．C
      ／5W        ・ 30レV
    r＝一〇．93 ’ r＝一〇．／O
  ■■■Bとod（メθr∠一」 ＝fCθ亡θs診












































































       ／
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protein bound
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